References
- Li FP, Fraumeni JF Jr, Mulvihill JJ, et al A cancer family syndrome in twenty-four kindreds. Cancer Res 1988;48:5358–5362.
- Olivier M, Goldgar DE, Sodha N, et al Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003;63:6643–6650.
- Larson RA. Therapy-related myeloid neoplasms. Haematologica 2009;94:454–459.
- Kroger N, Brand R, van Biezen A, et al Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica 2009;94:542–549.
- Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–331.
- Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001;19:1405–1413.
- Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008;22:240–248.
- Gonzalez KD, Buzin CH, Noltner KA, et al High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet 2009;46:689–693.